cilostazol has been researched along with cardiovascular agents in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (23.68) | 29.6817 |
| 2010's | 25 (65.79) | 24.3611 |
| 2020's | 4 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Ohhashi, T; Yashiro, Y | 1 |
| Daida, H; Kurata, T; Miyauchi, K; Okazaki, S; Sato, H; Shimada, K; Yokoyama, T | 1 |
| Brass, EP; Hiatt, WR; Lewis, RJ; Lipicky, R; Murphy, J | 1 |
| Donnelly, R; Rowlands, TE | 1 |
| Dimmeler, S; Potente, M | 1 |
| Dindyal, S; Kyriakides, C; Sharma, P | 1 |
| Hirose, Y; Mitani, K; Miyakoda, G; Nagasawa, M; Okada, K; Okutsu, R; Takase, H; Yabuuchi, Y; Yoshikawa, T | 1 |
| Badger, SA; Lee, B; O'Donnell, ME; Sharif, MA; Soong, CV; Young, IS | 1 |
| Chi, YW; Lavie, CJ; Milani, RV; White, CJ | 1 |
| Ando, M; Hida, K; Ishida, A; Kawasaki, T; Matsumoto, T; Matsuzaki, K; Miyata, T; Nishibe, T; Obitsu, Y; Ohta, T; Shigematsu, H; Shindo, S; Yasugi, T | 1 |
| Huisinga, JM; Johanning, JM; Pipinos, II; Stergiou, N | 1 |
| Choi, JR; Chung, JY; Jang, SB; Kim, K; Lee, D; Lee, J; Lee, YJ; Lim, LA; Park, JW; Park, K; Park, MS; Yoon, H | 1 |
| Hirano, K; Iida, O; Kawasaki, D; Soga, Y; Suzuki, K; Yamaoka, T | 1 |
| Hattori, K; Ito, H; Konno, H; Setou, M; Tanaka, H; Unno, N; Yamamoto, N; Zaima, N | 1 |
| Hattori, H; Ishihara, M; Nagata, M; Takase, B; Tanaka, Y | 1 |
| Hirano, K; Iida, O; Kawasaki, D; Nanto, K; Shintani, Y; Soga, Y; Suematsu, N; Suzuki, K; Takahara, M; Uematsu, M; Yamaoka, T | 1 |
| Bae, SK; Choi, WK; Oh, E; Park, JB; Park, S; Seo, JH; Sung, YJ | 1 |
| Casanegra, AI; Iftikhar, O; Oliveros, K; Tafur, AJ | 1 |
| Aggeli, K; Filis, K; Galyfos, G; Geropapas, G; Sianou, A; Sigala, F | 1 |
| Antzelevitch, C; Barajas-Martinez, H; Gurabi, Z; Hu, D; Koncz, I; Patocskai, B | 1 |
| Iida, O; Kawasaki, D; Matoba, S; Nanto, S; Soga, Y; Takahara, M; Yokoi, H; Zen, K | 1 |
| Comerota, AJ; Kasper, GC; Lurie, F; Russell, TE; Seiwert, AJ | 1 |
| de Donato, G; Galzerano, G; Giannace, G; Mele, M; Setacci, C; Setacci, F | 1 |
| Hara, H; Imai, T; Matsukawa, H; Shimazawa, M; Takagi, T; Tsuruma, K | 1 |
| Ando, K; Fukunaga, M; Hirano, K; Iida, O; Miyashita, Y; Shintani, Y; Soga, Y; Suzuki, K; Takahara, M; Tsuchiya, T; Yamaoka, T; Yamauchi, Y; Zen, K | 1 |
| Ando, K; Fujihara, M; Iida, O; Soga, Y; Tomoi, Y | 1 |
| Kim, YJ; Kwon, SU; Lee, J; Seo, WK | 1 |
| Anastasiadou, C; Galyfos, G; Geropapas, G; Giannakakis, S; Kastrisios, G; Kerasidis, S; Maltezos, C; Papacharalampous, G; Papapetrou, A; Sachmpazidis, I | 1 |
| Aodo, K; Edahiro, R; Hamasaki, T; Iida, O; Inoue, N; Kawasaki, D; Soga, Y; Suzuki, K; Urasawa, K; Yokoi, Y; Zen, K | 1 |
| Chen, WJ; Chen, YH; Hsu, YJ; Lin, KH; Yeh, YH | 1 |
| Alzamora, M; Forés, R; Giner-Soriano, M; Heras, A; Marsal, JR; Morros, R; Pera, G; Real, J; Ribes, E; Serna, MC | 1 |
| Doijiri, T; Hozawa, K; Ikeda, U; Kuwahara, K; Miura, T; Miyashita, Y; Soga, Y | 1 |
| Li, H; Ma, L; Qian, W; Shan, T; Xie, X; You, C; Zhang, T | 1 |
| Abraham, B; Banerjee, S; Megaly, M; Mekaiel, A; Saad, M; Shishehbor, MH; Soukas, P | 1 |
| Adachi, A; Bolstad, F; Fujimura, N; Ichihashi, S; Iwakoshi, S; Kichikawa, K; Kyuragi, R; Nagatomi, S; Obayashi, K; Saeki, K; Shibata, T; Yamamoto, H | 1 |
| Berceli, SA; DeSart, K; He, Y; Irwin, A; Kubilis, PS; Nelson, PR; Tran-Son-Tay, R | 1 |
| Cho, JG; Jeong, HK; Jin, IT; Lee, KH; Park, HW; Yoon, N | 1 |
| Chen, W; Cheng, Y; Huang, Y; Jiang, Y; Luo, H; Yu, W; Zhang, X | 1 |
9 review(s) available for cilostazol and cardiovascular agents
| Article | Year |
|---|---|
Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk.
Topics: Algorithms; Cardiovascular Agents; Cardiovascular Diseases; Cilostazol; Humans; Risk Assessment; Tetrazoles; Vasodilator Agents | 2006 |
Medical therapy for intermittent claudication.
Topics: Aged; Angiogenic Proteins; Animals; Cardiovascular Agents; Cilostazol; Collateral Circulation; Female; Genetic Therapy; Humans; Intermittent Claudication; Lower Extremity; Male; Neovascularization, Physiologic; Peripheral Vascular Diseases; Phosphodiesterase Inhibitors; Regional Blood Flow; Stem Cell Transplantation; Tetrazoles; Treatment Outcome | 2007 |
Safety and efficacy of cilostazol in the management of intermittent claudication.
Topics: Cardiovascular Agents; Cilostazol; Exercise Tolerance; Humans; Intermittent Claudication; Peripheral Vascular Diseases; Quality of Life; Tetrazoles; Treatment Outcome | 2008 |
Prevention of Femoropopliteal In-Stent Restenosis With Cilostazol: A Meta-Analysis.
Topics: Cardiovascular Agents; Cilostazol; Endovascular Procedures; Femoral Artery; Humans; Odds Ratio; Peripheral Arterial Disease; Popliteal Artery; Protective Factors; Recurrence; Risk Factors; Stents; Tetrazoles; Time Factors; Treatment Outcome; Vascular Patency | 2016 |
Meta-Analysis of Studies Evaluating the Effect of Cilostazol on Major Outcomes After Carotid Stenting.
Topics: Angioplasty; Cardiovascular Agents; Carotid Stenosis; Chi-Square Distribution; Cilostazol; Humans; Myocardial Infarction; Odds Ratio; Recurrence; Risk Assessment; Risk Factors; Stents; Stroke; Tetrazoles; Time Factors; Treatment Outcome | 2016 |
Restenosis after Coronary and Peripheral Intervention: Efficacy and Clinical Impact of Cilostazol.
Topics: Cardiovascular Agents; Cilostazol; Coronary Artery Disease; Coronary Restenosis; Endovascular Procedures; Humans; Peripheral Arterial Disease; Recurrence; Risk Factors; Tetrazoles; Treatment Outcome | 2017 |
Effectiveness and feasibility of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.
Topics: Brain Ischemia; Cardiovascular Agents; Cerebral Infarction; Cilostazol; Humans; Intracranial Aneurysm; Outcome Assessment, Health Care; Subarachnoid Hemorrhage; Vasospasm, Intracranial | 2020 |
Outcomes with cilostazol after endovascular therapy of peripheral artery disease.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cardiovascular Agents; Cilostazol; Endovascular Procedures; Female; Humans; Limb Salvage; Male; Middle Aged; Observational Studies as Topic; Peripheral Arterial Disease; Protective Factors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2019 |
Effectiveness comparisons of drug therapies for postoperative aneurysmal subarachnoid hemorrhage patients: network meta‑analysis and systematic review.
Topics: Cardiovascular Agents; Cilostazol; Humans; Intracranial Aneurysm; Network Meta-Analysis; Neuroprotective Agents; Nimodipine; Postoperative Period; Prognosis; Randomized Controlled Trials as Topic; Subarachnoid Hemorrhage; Treatment Outcome | 2021 |
9 trial(s) available for cilostazol and cardiovascular agents
| Article | Year |
|---|---|
Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atorvastatin; Cardiovascular Agents; Cholesterol, LDL; Cilostazol; Combined Modality Therapy; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Tetrazoles; Ticlopidine; Treatment Outcome; Ultrasonography, Interventional | 2004 |
The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Ankle; Aorta; Biomarkers; Blood Pressure; Brachial Artery; Cardiovascular Agents; Cilostazol; Compliance; Double-Blind Method; Female; Humans; Lipids; Male; Middle Aged; Oxygen; Peripheral Vascular Diseases; Prospective Studies; Quality of Life; Recovery of Function; Surveys and Questionnaires; Tetrazoles; Time Factors; Treatment Outcome; Walking | 2009 |
Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study.
Topics: Administration, Oral; Adult; Area Under Curve; Asian People; Cardiovascular Agents; Chemistry, Pharmaceutical; Cilostazol; Cross-Over Studies; Delayed-Action Preparations; Female; Food-Drug Interactions; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Republic of Korea; Tetrazoles; Therapeutic Equivalency; Young Adult | 2011 |
Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cholinergic Antagonists; Cilostazol; Drug Therapy, Combination; Endothelium, Vascular; Female; Health Behavior; Hemodynamics; Humans; Hypercholesterolemia; Life Style; Lipids; Male; Middle Aged; Platelet Aggregation Inhibitors; Probucol; Prospective Studies; Stroke, Lacunar; Tetrazoles; Vasodilation | 2014 |
Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Cilostazol; Constriction, Pathologic; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Japan; Logistic Models; Male; Middle Aged; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Popliteal Artery; Propensity Score; Prospective Studies; Prosthesis Design; Recurrence; Registries; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Patency | 2017 |
Efficacy of CilostAzol for Below-the-Knee Artery Disease after Balloon AnGioplasty in PatiEnts with Severe Limb Ischemia (CABBAGE Trial).
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angiography; Angioplasty, Balloon; Cardiovascular Agents; Cilostazol; Female; Humans; Ischemia; Japan; Leg; Limb Salvage; Male; Middle Aged; Peripheral Arterial Disease; Prospective Studies; Recurrence; Severity of Illness Index; Tetrazoles; Time Factors; Treatment Outcome | 2017 |
Design and Rationale of the Intima-Medial Thickness Sub-Study of the PreventIon of CArdiovascular Events in iSchemic Stroke Patients with High Risk of Cerebral hemOrrhage (PICASSO-IMT) Study.
Topics: Brain Ischemia; Cardiovascular Agents; Carotid Artery Diseases; Carotid Artery, Common; Carotid Intima-Media Thickness; Cerebral Hemorrhage; Cilostazol; Clinical Protocols; Double-Blind Method; Humans; Predictive Value of Tests; Probucol; Prospective Studies; Republic of Korea; Research Design; Risk Factors; Stroke; Tetrazoles; Time Factors; Treatment Outcome | 2017 |
Sustained Effectiveness of Cilostazol After Endovascular Treatment of Femoropopliteal Lesions: Midterm Follow-up From the Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) Study.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Cilostazol; Female; Femoral Artery; Humans; Intermittent Claudication; Male; Middle Aged; Peripheral Arterial Disease; Popliteal Artery; Recurrence; Risk Factors; Stents; Time Factors; Treatment Outcome; Vascular Patency | 2018 |
Drug-Eluting Versus Bare-Metal Stent Implantation With or Without Cilostazol in the Treatment of the Superficial Femoral Artery.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cardiovascular Agents; Cilostazol; Double-Blind Method; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Limb Salvage; Male; Metals; Middle Aged; Peripheral Arterial Disease; Prospective Studies; Prosthesis Design; Recurrence; Risk Factors; Stents; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Patency | 2018 |
20 other study(ies) available for cilostazol and cardiovascular agents
| Article | Year |
|---|---|
Effects of cilostazol, a selective cyclic AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Arterioles; Cardiovascular Agents; Cilostazol; Endothelium, Vascular; In Vitro Techniques; Phosphodiesterase Inhibitors; Rabbits; Spinal Cord; Tetrazoles; Vasodilation; Vasodilator Agents | 2002 |
NO targets SIRT1: a novel signaling network in endothelial senescence.
Topics: Aging; Animals; Cardiovascular Agents; Cellular Senescence; Cilostazol; Drug Design; Endothelium, Vascular; Humans; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphodiesterase Inhibitors; Signal Transduction; Sirtuin 1; Sirtuins; Tetrazoles | 2008 |
Regarding "Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions".
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Cardiovascular Agents; Cilostazol; Constriction, Pathologic; Female; Femoral Artery; Humans; Male; Popliteal Artery; Research Design; Secondary Prevention; Tetrazoles; Treatment Outcome; Vascular Patency | 2008 |
Cilostazol inhibits modified low-density lipoprotein uptake and foam cell formation in mouse peritoneal macrophages.
Topics: Animals; Cardiovascular Agents; CD36 Antigens; Cells, Cultured; Cholesterol Esters; Cilostazol; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Relationship, Drug; Endocytosis; Foam Cells; Lipoproteins, LDL; Macrophages, Peritoneal; Mice; Phosphodiesterase 3 Inhibitors; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Protein Kinase C; Protein Kinase Inhibitors; Scavenger Receptors, Class A; Tetrazoles | 2009 |
Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
Topics: Adult; Aged; Aged, 80 and over; Ankle Brachial Index; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Cilostazol; Disease Progression; Epoprostenol; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Quality of Life; Risk Assessment; Risk Factors; Severity of Illness Index; Societies, Medical; Tetrazoles; Time Factors; Treatment Outcome; Vascular Surgical Procedures; Vasodilator Agents | 2010 |
The effect of pharmacological treatment on gait biomechanics in peripheral arterial disease patients.
Topics: Aged; Biomechanical Phenomena; Cardiovascular Agents; Case-Control Studies; Cilostazol; Dyskinesias; Female; Gait; Humans; Leg; Male; Middle Aged; Pentoxifylline; Peripheral Vascular Diseases; Range of Motion, Articular; Tetrazoles; Time Factors; Treatment Outcome; Walking | 2010 |
Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Chi-Square Distribution; Cilostazol; Constriction, Pathologic; Female; Humans; Ischemia; Japan; Limb Salvage; Logistic Models; Male; Peripheral Arterial Disease; Popliteal Artery; Radiography; Registries; Retrospective Studies; Secondary Prevention; Tetrazoles; Time Factors; Treatment Outcome; Wound Healing | 2012 |
Cilostazol inhibits accumulation of triglycerides in a rat model of carotid artery ligation.
Topics: Animals; Cardiovascular Agents; Carotid Artery, Common; Carotid Stenosis; Cholesterol, HDL; Cilostazol; Disease Models, Animal; Heme; Hemodynamics; Ligation; Male; Phosphodiesterase 3 Inhibitors; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Tetrazoles; Time Factors; Triglycerides | 2013 |
Effect of Cilostazol Following Endovascular Intervention for Peripheral Artery Disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alloys; Cardiovascular Agents; Cilostazol; Databases, Factual; Endovascular Procedures; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Peripheral Arterial Disease; Proportional Hazards Models; Prosthesis Design; Recurrence; Retrospective Studies; Risk Factors; Stents; Tetrazoles; Time Factors; Treatment Outcome; Vascular Patency | 2015 |
Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylate.
Topics: Administration, Oral; Animals; Area Under Curve; Benzenesulfonates; Biological Availability; Cardiovascular Agents; Chemistry, Pharmaceutical; Cilostazol; Drug Stability; Gastrointestinal Absorption; Male; Mesylates; Rats, Sprague-Dawley; Solubility; Technology, Pharmaceutical; Tetrazoles; Wettability | 2015 |
Cellular and ionic mechanisms underlying the effects of cilostazol, milrinone, and isoproterenol to suppress arrhythmogenesis in an experimental model of early repolarization syndrome.
Topics: Action Potentials; Animals; Cardiac Electrophysiology; Cardiovascular Agents; Cilostazol; Death, Sudden, Cardiac; Disease Models, Animal; Dogs; Electrocardiography; Ion Channels; Isoproterenol; Milrinone; Tachycardia, Ventricular; Tetrazoles; Ventricular Fibrillation | 2016 |
Cilostazol May Improve Maturation Rates and Durability of Vascular Access for Hemodialysis.
Topics: Aged; Arteriovenous Shunt, Surgical; Cardiovascular Agents; Case-Control Studies; Cilostazol; Drug Administration Schedule; Female; Humans; Linear Models; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Phosphodiesterase 3 Inhibitors; Postoperative Complications; Renal Dialysis; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome | 2017 |
The phosphodiesterase III inhibitor cilostazol protects the brain microvasculature from collagenase injury.
Topics: Administration, Oral; Animals; Brain; Cardiovascular Agents; Cells, Cultured; Cilostazol; Collagen Type IV; Collagenases; Cytoskeleton; Disease Models, Animal; Extracellular Matrix; Humans; Intracranial Hemorrhages; Male; Mice; Microscopy, Electron, Transmission; Microvessels; Neuroprotective Agents; Phosphodiesterase 3 Inhibitors; Random Allocation; Tetrazoles | 2017 |
Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Cilostazol; Databases, Factual; Endovascular Procedures; Female; Femoral Artery; Humans; Japan; Male; Middle Aged; Peripheral Arterial Disease; Popliteal Artery; Recurrence; Registries; Retrospective Studies; Risk Factors; Stents; Time Factors; Treatment Outcome; Vascular Patency | 2017 |
Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia.
Topics: Adult; Amputation, Surgical; Ankle Brachial Index; Anticoagulants; Arteritis; Aspirin; Cardiovascular Agents; Cilostazol; Critical Illness; Drug Therapy, Combination; Female; Heparin, Low-Molecular-Weight; Humans; Iloprost; Infusions, Intravenous; Ischemia; Limb Salvage; Lower Extremity; Male; Marijuana Abuse; Marijuana Smoking; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Smoking; Smoking Cessation; Tetrazoles; Thromboangiitis Obliterans; Time Factors; Treatment Outcome; Vasodilator Agents | 2017 |
MicroRNA-132 targeting PTEN contributes to cilostazol-promoted vascular smooth muscle cell differentiation.
Topics: 3' Untranslated Regions; Animals; Binding Sites; Calcium-Binding Proteins; Calponins; Cardiovascular Agents; Carotid Arteries; Carotid Artery Injuries; Cell Differentiation; Cells, Cultured; Cilostazol; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Down-Regulation; Gene Expression Regulation, Enzymologic; Male; Microfilament Proteins; MicroRNAs; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Promoter Regions, Genetic; PTEN Phosphohydrolase; Rats, Wistar; Signal Transduction | 2018 |
Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Agents; Cerebrovascular Disorders; Cilostazol; Databases, Factual; Drug Interactions; Electronic Health Records; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Patient Safety; Pentoxifylline; Peripheral Arterial Disease; Phosphodiesterase 3 Inhibitors; Polypharmacy; Primary Health Care; Retrospective Studies; Risk Assessment; Risk Factors; Spain; Time Factors; Treatment Outcome | 2018 |
Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cardiovascular Agents; Cilostazol; Constriction, Pathologic; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Japan; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Progression-Free Survival; Prosthesis Design; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Vascular Calcification; Vascular Patency | 2019 |
Heterogeneous and dynamic lumen remodeling of the entire infrainguinal vein bypass grafts in patients.
Topics: Aged; Cardiovascular Agents; Cilostazol; Computed Tomography Angiography; Female; Humans; Longitudinal Studies; Lower Extremity; Male; Middle Aged; Peripheral Arterial Disease; Phlebography; Prospective Studies; Time Factors; Treatment Outcome; Vascular Grafting; Vascular Remodeling; Veins | 2020 |
Positive chronotropic effects of theophylline and cilostazol in patients with symptomatic sick sinus syndrome who have declined permanent pacing.
Topics: Aged; Cardiac Pacing, Artificial; Cardiovascular Agents; Cilostazol; Drug Substitution; Female; Heart Rate; Humans; Male; Middle Aged; Recovery of Function; Retrospective Studies; Sick Sinus Syndrome; Theophylline; Time Factors; Treatment Outcome; Treatment Refusal | 2020 |